The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.
Tom Samuel Waddell
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Merck Serono (U); Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Merck Serono; Roche
Clare Peckitt
No relevant relationships to disclose
Bijal Patel
No relevant relationships to disclose
David Gonzalez de Castro
No relevant relationships to disclose
Andrew Wotherspoon
No relevant relationships to disclose
Gary William Middleton
Honoraria - Roche; Sanofi
Jonathan Wadsley
No relevant relationships to disclose
David Ferry
Research Funding - Amgen
Wasat Mansoor
No relevant relationships to disclose
Tom David Lewis Crosby
No relevant relationships to disclose
Fareeda Y. Coxon
No relevant relationships to disclose
David Smith
No relevant relationships to disclose
Justin S. Waters
No relevant relationships to disclose
Timothy Iveson
Consultant or Advisory Role - Roche (U)
Stephen Falk
No relevant relationships to disclose
Sarah Slater
No relevant relationships to disclose
Alicia Frances Clare Okines
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; Celgene; Merck Serono; Novartis; Roche; Sanofi